MyFinsight
Home
Blog
About
Contact
Proceeds from exercise of
stock options
$198K
Net cash provided by
financing activities
$129K
Canceled cashflow
$69K
Net increase
(decrease) in cash and cash...
-$55,445K
Canceled cashflow
$129K
Sales and maturities
of marketable...
$58,121K
Stock-based compensation
$3,823K
Noncash operating lease
expense
$624K
Accounts payable
$490K
Depreciation and
amortization
$83K
Loss on disposal of
property and equipment
-$2K
Payments of deferred
offering costs
$69K
Net cash provided by
(used in) investing...
-$39,308K
Net cash used in
operating activities
-$16,266K
Canceled cashflow
$58,121K
Canceled cashflow
$5,022K
Purchases of marketable
securities
$97,117K
Net loss
-$14,456K
Accrued expenses
-$3,525K
Purchase of property and
equipment
$312K
Prepaid expenses and
other current assets
$1,616K
Operating lease
liabilities
-$1,296K
Accretion of
premiums/discounts on marketable...
$395K
Back
Back
Cash Flow
Contineum Therapeutics, Inc. (CTNM)
Contineum Therapeutics, Inc. (CTNM)
source: myfinsight.com